Blood stem cell transplantation for patients with relapsiong-remitting
Haematopoetic Stem Cell Therapy for Patients with Inflammatory Multiple Sclerosis Failing Alternate Approved Therapy: A Randomized Study
What it found
We found no results in the registry or in papers.
What was tested
Compared with
- Natalizumab
Integrin alpha-4/beta-1 inhibitor|Integrin alpha-4/beta-7 inhibitor
What it measured
Main measures
Disease progression, defined as a 1-point increase in the EDSS on consecutive evaluations at least 6 months apart and not due to a non-MS disease process. Patients will be followed for 5 years after randomization.
Disability progression
Other measures (1)
Number of relapses
Relapses
Who could take part
Relapsing MS
Show the full criteria
Inclusion criteria
Inclusion: 1. Age between 18 -55, inclusive. Exclusion: 1. Any illness that in the opinion of the investigators would jeopardize the ability of the patient to tolerate aggressive chemotherapy.
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
To assess the efficacy of autologous HSCT versus the FDA approved
Loading reviews and guidelines…
History
Started
Dec 2010